Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic.
Tonini C, Bianchi A, Esposito M, Esposito I, Giacomelli T, Young E, Lanckriet H, Whiffen Z, Pavlickova M, Entiriwaa D, Principato E, Roscilli G, Piconese S, Lione L, Salvatori E, Pinto E, Ciliberto G, Aurisicchio L, Walker A, Palombo F.J Immunother Cancer. 2026 May 13;14(5):e013812. doi: 10.1136/jitc-2025-013812.PMID: 42128520

Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8⁺ T cells in treated muscle and limits tumor infiltration.
Andrea B, Mauro E, Tiziano G, Ilaria E, Claudia T, Luigi A, Fabio P.Mol Ther Oncol. 2026 May 28;34(3):201248. doi: 10.1016/j.omton.2026.201248. eCollection 2026 Sep 17.PMID: 42440858

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy.
Salvatori E, Lione L, Compagnone M, Pinto E, Conforti A, Ciliberto G, Aurisicchio L, Palombo F. 
npj Vaccines 2022 volume 7, 15.

Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition.
Lione L, Salvatori E, Petrazzuolo A, Massacci A, Maggio R, Conforti A, Compagnone M, Aurisicchio L, Ciliberto G, Palombo F.
Oncoimmunology 2021 23;10(1):1898832.

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L, Salvatori E, Lione L, Bandini S, Pallocca M, Maggio R, Fanciulli M, De Nicola F, Goeman F, Ciliberto G, Conforti A, Luberto L, Palombo F.  
J Exp Clin Cancer Res 2019, 14;38(1):78.